Jill Showalter
Optometrist · Vienna, WVNPI 1659424877
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2022 at $2,401 and has fallen 63.2% since, to $883 in 2025. Among optometrist clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $53.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- Tarsus Pharmaceuticals, Inc.$1K
- Novartis$1K
- Eyevance Pharmaceuticals LLC$1K
- Sun Pharmaceutical Industries Inc.$1K
- Bausch & Lomb Americas Inc.$553
- plus $3K from 17 others
What the payments were for
- Consulting fees$2,74829%
- Travel & lodging$1,52216%
- Food & beverage$5,29455%
- Gifts$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 14 | $2,045 |
| Tarsus Pharmaceuticals, Inc. | 14 | $1,191 |
| Novartis | 3 | $1,168 |
| Eyevance Pharmaceuticals LLC | 6 | $1,075 |
| Sun Pharmaceutical Industries Inc. | 57 | $1,053 |
| Bausch & Lomb Americas Inc. | 17 | $553 |
| Tearlab Corp | 1 | $500 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $286 |
| AbbVie(2 entities) | 8 | $270 |
| Johnson & Johnson Vision Care, Inc. | 7 | $246 |
| Coopervision Inc. | 4 | $237 |
| Oyster Point Pharma, Inc. | 13 | $229 |
| Alcon | 4 | $164 |
| Mallinckrodt Hospital Products Inc. | 6 | $138 |
| Dompe US, Inc. | 1 | $123 |
| LKC Technologies, Inc. | 1 | $100 |
| Shire North American Group Inc | 5 | $83 |
| Kala Pharmaceuticals, Inc. | 2 | $39 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Plexus Optix, Inc. | 1 | $18 |
| Harrow Eye, LLC | 1 | $18 |
| Thea Pharma Inc. | 1 | $16 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$1,551
- AmnioGraft$1,551
- XIIDRA$1,118
- Flarex$1,000
- XDEMVY$900
- TearLab Osmolarity System$500
- RESTASIS$125
- Oxervate$123
- Acuvue$121
- INFUSE$100
How this compares
$9,602 in reported general payments places this provider in the 95th percentile of 210 optometrist providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 145 | $202,730 |
| CequaCyclosporine | 135 | $118,949 |
| XiidraLifitegrast | 61 | $88,863 |
| XdemvyLotilaner | 29 | $54,048 |
| EysuvisLoteprednol Etabonate | 66 | $32,156 |
| TyrvayaVarenicline Tartrate | 29 | $27,697 |
| VevyeCyclosporine | 21 | $18,432 |
| Fluorometholone | 209 | $15,110 |
| MieboPerfluorohexyloctane/Pf | 15 | $10,923 |
| LumiganBimatoprost | 21 | $10,041 |
| Cyclosporine | 16 | $9,490 |
| Loteprednol Etabonate | 67 | $7,164 |
| Epinastine Hcl | 49 | $5,141 |
| Lotemax SmLoteprednol Etabonate | 17 | $4,140 |
| FlarexFluorometholone Acetate | 21 | $2,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $270 | $212,771166 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,053 | $118,949135 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $553 | $99,78576 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,191 | $54,04829 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $39 | $32,15666 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $229 | $27,69729 claims |
| Harrow Eye, LLCVevye | $18 | $18,43221 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm | $286 | $11,30484 claims |
| Eyevance Pharmaceuticals LLCFlarex | $1,075 | $2,64421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 optometrist providers in West Virginia.
Other optometrist in Vienna
- Susannah NeffVienna$6K
- Katie PalmerVienna$3K
- Gregory MooreBuckhannon$28K
- Steven PotwinSaint Albans$24K
- Kayla CampbellBarboursville$16K
- Lee MooreCharles Town$10K
- Bryce PeekBarboursville$8K
- James FickClarksburg$8K
- Laura Suppa SammonsCharleston$8K
- Mark WhittingtonCharleston$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.